Tesamorelin 5mg

Tesamorelin 5mg (Vial)

Tesamorelin 5mg is a research-grade peptide supplied as a sterile lyophilised vial for controlled analytical and in-vitro studies. It is examined in scientific environments for its involvement in growth-hormone–related signalling, GHRH pathway modelling, and peptide stability analysis under laboratory conditions.
This batch has been tested for purity, confirming suitability for regulated research applications.

Key Research Features

• 5mg Tesamorelin supplied in a sterile lyophilised vial

• Batch tested for purity (internal analytical verification)

• Research-grade handling standards

• Stable peptide structure suitable for analytical and in-vitro studies

• Useful for GHRH pathway modelling and receptor interaction studies

• Secure, tamper-evident laboratory packaging

Common Research Areas

Tesamorelin is explored across laboratory and in-vitro models focusing on:

• Growth-hormone–related signalling pathways

• GHRH receptor interaction and downstream biological responses

• Hormone-communication models in controlled environments

• Pathway mapping for endocrine-linked signalling

• Peptide stability and degradation behaviour under laboratory conditions

Researchers utilise Tesamorelin to examine how GHRH analogues behave in signalling and receptor-interaction studies. No therapeutic or human application is implied.

Research Handling Notes

• Intended strictly for analytical and in-vitro laboratory research

• Batch tested for purity

• No preparation, dosing, or usage instructions are supplied

Storage & Handling

• Store at 2–8°C in a temperature-controlled environment

• Protect from heat, moisture, and direct light

• Keep sealed until laboratory analysis

• Dispose of materials according to laboratory safety protocols

References (For Scientific Literature Context Only)

These publications are provided solely as background scientific literature relevant to Tesamorelin and GHRH analogues. They do not imply any usage or application of the product.

Falutz, J., et al. (2010). Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial. Journal of Clinical Endocrinology & Metabolism, 95(9), 4291–4304.
URL: https://pubmed.ncbi.nlm.nih.gov/20554713/

Stanley, T. L., et al. (2014). Effects of tesamorelin on visceral adipose tissue and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA, 312(4), 380–389.
URL: https://jamanetwork.com/journals/jama/fullarticle/1889139

Adrian, S., et al. (2019). The growth hormone–releasing hormone analogue tesamorelin decreases visceral adipose tissue and improves metabolic parameters. Growth Hormone & IGF Research, 45, 10–17.
URL: https://doi.org/10.1016/j.ghir.2019.01.003

Jordan, E. L., et al. (2021). Tesamorelin improves adipose tissue quality independent of changes in fat quantity. Clinical Infectious Diseases, 73(10), e3483–e3491.
URL: https://doi.org/10.1093/cid/ciaa213

Legal & Safety Notice

This product is supplied strictly for in-vitro laboratory research use only. It is not intended for human consumption, therapeutic use, or any in vivo application.

By purchasing this product, the buyer agrees:

• They are a legal adult (18+).

• The compound will be handled only by qualified professionals in controlled laboratory settings.

• Use is restricted to lawful in-vitro research purposes only.

• The buyer assumes full responsibility for proper handling, storage, and laboratory application.

• No warranties are provided beyond suitability for stated research use.

• Phoenix Biolabs accepts no liability for misuse, misapplication, or unauthorised use.

⚠️ For Research Use Only. Not for Human or Veterinary Use.